Alzheimers Drug Market Size to Hit USD 7.13 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Alzheimer’s Drug Market

5.1. COVID-19 Landscape: Alzheimer’s Drug Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Alzheimer’s Drug Market, By Drug Class

8.1. Alzheimer’s Drug Market Revenue and Volume, by Drug Class

8.1.1. Cholinesterase Inhibitors

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. NMDA Receptor Antagonists

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Combination Drugs

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Anti-Amyloid Monoclonal Antibodies

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Tau Aggregation Inhibitors

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Alzheimer’s Drug Market, By Disease Stage

9.1. Alzheimer’s Drug Market Revenue and Volume, by Disease Stage

9.1.1. Early Stage / Mild Alzheimer’s

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Moderate Alzheimer’s

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Severe Alzheimer’s

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Prodromal / Mild Cognitive Impairment (MCI)

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Alzheimer’s Drug Market, By Mechanism of Action

10.1. Alzheimer’s Drug Market Revenue and Volume, by Mechanism of Action

10.1.1. Amyloid Beta Inhibitors

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Others

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. Global Alzheimer’s Drug Market, By Drug Type

11.1. Alzheimer’s Drug Market Revenue and Volume, by Drug Type

11.1.1. Biologics

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Small Molecules

11.1.2.1. Market Revenue and Volume Forecast

Chapter 12. Global Alzheimer’s Drug Market, By Distribution Channel

12.1. Alzheimer’s Drug Market Revenue and Volume, by Distribution Channel

12.1.1. Hospital Pharmacies

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Retail Pharmacies

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Retail Pharmacies

12.1.3.1. Market Revenue and Volume Forecast

Chapter 13. Global Alzheimer’s Drug Market, By End User

13.1. Alzheimer’s Drug Market Revenue and Volume, by End User

13.1.1. Hospitals

13.1.1.1. Market Revenue and Volume Forecast

13.1.2. Specialty Clinics & Neurology Centers

13.1.2.1. Market Revenue and Volume Forecast

13.1.3. Homecare Settings

13.1.3.1. Market Revenue and Volume Forecast

13.1.4. Academic & Research Institutions

13.1.4.1. Market Revenue and Volume Forecast

Chapter 14. Global Alzheimer’s Drug Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Volume Forecast, by Drug Class

14.1.2. Market Revenue and Volume Forecast, by Disease Stage

14.1.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.1.4. Market Revenue and Volume Forecast, by Drug Type

14.1.5. Market Revenue and Volume Forecast, by Distribution Channel

14.1.6. Market Revenue and Volume Forecast, by End User

14.1.7. U.S.

14.1.7.1. Market Revenue and Volume Forecast, by Drug Class

14.1.7.2. Market Revenue and Volume Forecast, by Disease Stage

14.1.7.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.1.7.4. Market Revenue and Volume Forecast, by Drug Type

14.1.8. Market Revenue and Volume Forecast, by Distribution Channel

14.1.8.1. Market Revenue and Volume Forecast, by End User

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Volume Forecast, by Drug Class

14.1.9.2. Market Revenue and Volume Forecast, by Disease Stage

14.1.9.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.1.9.4. Market Revenue and Volume Forecast, by Drug Type

14.1.10. Market Revenue and Volume Forecast, by Distribution Channel

14.1.11. Market Revenue and Volume Forecast, by End User

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Volume Forecast, by Drug Class

14.2.2. Market Revenue and Volume Forecast, by Disease Stage

14.2.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.4. Market Revenue and Volume Forecast, by Drug Type

14.2.5. Market Revenue and Volume Forecast, by Distribution Channel

14.2.6. Market Revenue and Volume Forecast, by End User

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Volume Forecast, by Drug Class

14.2.8.2. Market Revenue and Volume Forecast, by Disease Stage

14.2.8.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.9. Market Revenue and Volume Forecast, by Drug Type

14.2.10. Market Revenue and Volume Forecast, by Distribution Channel

14.2.10.1. Market Revenue and Volume Forecast, by End User

14.2.11. Germany

14.2.11.1. Market Revenue and Volume Forecast, by Drug Class

14.2.11.2. Market Revenue and Volume Forecast, by Disease Stage

14.2.11.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.12. Market Revenue and Volume Forecast, by Drug Type

14.2.13. Market Revenue and Volume Forecast, by Distribution Channel

14.2.14. Market Revenue and Volume Forecast, by End User

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Volume Forecast, by Drug Class

14.2.15.2. Market Revenue and Volume Forecast, by Disease Stage

14.2.15.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.15.4. Market Revenue and Volume Forecast, by Drug Type

14.2.16. Market Revenue and Volume Forecast, by Distribution Channel

14.2.16.1. Market Revenue and Volume Forecast, by End User

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Volume Forecast, by Drug Class

14.2.17.2. Market Revenue and Volume Forecast, by Disease Stage

14.2.17.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.2.17.4. Market Revenue and Volume Forecast, by Drug Type

14.2.18. Market Revenue and Volume Forecast, by Distribution Channel

14.2.18.1. Market Revenue and Volume Forecast, by End User

14.3. APAC

14.3.1. Market Revenue and Volume Forecast, by Drug Class

14.3.2. Market Revenue and Volume Forecast, by Disease Stage

14.3.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.4. Market Revenue and Volume Forecast, by Drug Type

14.3.5. Market Revenue and Volume Forecast, by Distribution Channel

14.3.6. Market Revenue and Volume Forecast, by End User

14.3.7. India

14.3.7.1. Market Revenue and Volume Forecast, by Drug Class

14.3.7.2. Market Revenue and Volume Forecast, by Disease Stage

14.3.7.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.7.4. Market Revenue and Volume Forecast, by Drug Type

14.3.8. Market Revenue and Volume Forecast, by Distribution Channel

14.3.9. Market Revenue and Volume Forecast, by End User

14.3.10. China

14.3.10.1. Market Revenue and Volume Forecast, by Drug Class

14.3.10.2. Market Revenue and Volume Forecast, by Disease Stage

14.3.10.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.10.4. Market Revenue and Volume Forecast, by Drug Type

14.3.11. Market Revenue and Volume Forecast, by Distribution Channel

14.3.11.1. Market Revenue and Volume Forecast, by End User

14.3.12. Japan

14.3.12.1. Market Revenue and Volume Forecast, by Drug Class

14.3.12.2. Market Revenue and Volume Forecast, by Disease Stage

14.3.12.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.12.4. Market Revenue and Volume Forecast, by Drug Type

14.3.12.5. Market Revenue and Volume Forecast, by Distribution Channel

14.3.12.6. Market Revenue and Volume Forecast, by End User

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Volume Forecast, by Drug Class

14.3.13.2. Market Revenue and Volume Forecast, by Disease Stage

14.3.13.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.3.13.4. Market Revenue and Volume Forecast, by Drug Type

14.3.13.5. Market Revenue and Volume Forecast, by Distribution Channel

14.3.13.6. Market Revenue and Volume Forecast, by End User

14.4. MEA

14.4.1. Market Revenue and Volume Forecast, by Drug Class

14.4.2. Market Revenue and Volume Forecast, by Disease Stage

14.4.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.4. Market Revenue and Volume Forecast, by Drug Type

14.4.5. Market Revenue and Volume Forecast, by Distribution Channel

14.4.6. Market Revenue and Volume Forecast, by End User

14.4.7. GCC

14.4.7.1. Market Revenue and Volume Forecast, by Drug Class

14.4.7.2. Market Revenue and Volume Forecast, by Disease Stage

14.4.7.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.7.4. Market Revenue and Volume Forecast, by Drug Type

14.4.8. Market Revenue and Volume Forecast, by Distribution Channel

14.4.9. Market Revenue and Volume Forecast, by End User

14.4.10. North Africa

14.4.10.1. Market Revenue and Volume Forecast, by Drug Class

14.4.10.2. Market Revenue and Volume Forecast, by Disease Stage

14.4.10.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.10.4. Market Revenue and Volume Forecast, by Drug Type

14.4.11. Market Revenue and Volume Forecast, by Distribution Channel

14.4.12. Market Revenue and Volume Forecast, by End User

14.4.13. South Africa

14.4.13.1. Market Revenue and Volume Forecast, by Drug Class

14.4.13.2. Market Revenue and Volume Forecast, by Disease Stage

14.4.13.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.13.4. Market Revenue and Volume Forecast, by Drug Type

14.4.13.5. Market Revenue and Volume Forecast, by Distribution Channel

14.4.13.6. Market Revenue and Volume Forecast, by End User

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Volume Forecast, by Drug Class

14.4.14.2. Market Revenue and Volume Forecast, by Disease Stage

14.4.14.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.4.14.4. Market Revenue and Volume Forecast, by Drug Type

14.4.14.5. Market Revenue and Volume Forecast, by Distribution Channel

14.4.14.6. Market Revenue and Volume Forecast, by End User

14.5. Latin America

14.5.1. Market Revenue and Volume Forecast, by Drug Class

14.5.2. Market Revenue and Volume Forecast, by Disease Stage

14.5.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.5.4. Market Revenue and Volume Forecast, by Drug Type

14.5.5. Market Revenue and Volume Forecast, by Distribution Channel

14.5.6. Market Revenue and Volume Forecast, by End User

14.5.7. Brazil

14.5.7.1. Market Revenue and Volume Forecast, by Drug Class

14.5.7.2. Market Revenue and Volume Forecast, by Disease Stage

14.5.7.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.5.7.4. Market Revenue and Volume Forecast, by Drug Type

14.5.8. Market Revenue and Volume Forecast, by Distribution Channel

14.5.8.1. Market Revenue and Volume Forecast, by End User

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Volume Forecast, by Drug Class

14.5.9.2. Market Revenue and Volume Forecast, by Disease Stage

14.5.9.3. Market Revenue and Volume Forecast, by Mechanism of Action

14.5.9.4. Market Revenue and Volume Forecast, by Drug Type

14.5.9.5. Market Revenue and Volume Forecast, by Distribution Channel

14.5.9.6. Market Revenue and Volume Forecast, by End User

Chapter 15. Company Profiles

15.1. Eisai Co., Ltd.

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Biogen Inc.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Eli Lilly and Company

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Roche Holding AG (Genentech)

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Acumen Pharmaceuticals

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Cassava Sciences

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Vaxxinity Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Alzamend Neuro

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Anavex Life Sciences

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Oryzon Genomics

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global alzheimers drug market is expected to increase from USD 3.94 billion in 2024 to USD 7.13 billion by 2034.

The alzheimers drug market is expected to grow at a compound annual growth rate (CAGR) of around 6.12% from 2025 to 2034.

The major players in the alzheimers drug market include Eisai Co., Ltd., Biogen Inc., Eli Lilly and Company, Roche Holding AG (Genentech), Acumen Pharmaceuticals, Cassava Sciences, Vaxxinity Inc. , Anavex Life Sciences, Alzamend Neuro, and Oryzon Genomics.

The driving factors of the alzheimers drug market are the rising incidence rates, increasing awareness, and advancements in both symptomatic and disease-modifying therapies.

North America region will lead the global alzheimers drug market during the forecast period 2025 to 2034.